Subcutaneous Immunoglobulin Use in Children

Kara Manolya; Somer Ayper

doi:https://dx.doi.org/10.5222/j.child.2017.146

Review

DOI :10.5222/j.child.2017.146 IUP :10.5222/j.child.2017.146 Full Text (PDF)

Subcutaneous Immunoglobulin Use in Children

Human plasma derived immunoglobulin products have been considered among treatment options for many of the disorders, particularly primary immune deficiencies. Immunoglobulins can be administered either intravenous (IV), subcutaneous (SC) or intramuscular (IM) route. In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs. Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review.

Keywords: Subcutaneous immunoglobulin, children, treatment

DOI :10.5222/j.child.2017.146 IUP :10.5222/j.child.2017.146 Full Text (PDF)

Çocuklarda Subkutan İmmünglobülin Kullanımı

Manolya Kara, Ayper Somer

nsan plazma kaynaklı immünglobülinler başta primer immün yetersizlik hastalıkları olmak üzere pek çok hastalığın tedavi seçenekleri arasında yer almaktadır. İmmünglobülin preparatları; intravenöz (IV), subkutan (SC) ya da intramüsküler (IM) yolla verilebilir. Son yıllarda subkutan immünglobülin (SIG) uygulaması, hasta konforunun daha yüksek, maliyetinin ve yan etki insidansının daha düşük olması nedeniyle tercih edilmektedir. Bu yazıda çocuk hastalarda SIG kullanımı ile ilgili güncel bilgiler özetlenmiştir.

Keywords: Subkutan immünglobülin, çocuk, tedavi

References

1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9:722-8. google scholar
2. Jolles S. Subcutaneous and intramuscular immune globulin therapy. www.uptodate.com. google scholar
3. Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2. google scholar
4. Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol 1956;1:318-56. google scholar
5. Hill LE, Mollison PL. MRC working party on hypogammaglobulinemia, collection of cases and design of trial, Chap. II, Hypogammaglobulinemia in the UK. Her Majesty’s Stationery Office: London, 1971: pp. 4-8. google scholar
6. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779. https://doi.org/10.1016/j.iac.2008.07.002 google scholar
7. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27:171. https://doi.org/10.1016/j.tmrv.2013.05.004 google scholar
8. Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014;6:71-83. https://doi.org/10.2217/imt.13.146 google scholar
9. Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: A retrospective cohort study. PLoS One 2016;11: e0159993. https://doi.org/10.1371/journal.pone.0159993 google scholar
10. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92-7. https://doi.org/10.1111/j.1529-8027.2011.00330.x google scholar
11. US Food and Drug Administration (FDA) approval: http://www.fda.gov/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/ fractionatedplasmaproducts/ucm414117.htm (Accessed on September 19, 2014). google scholar
12. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734. https://doi.org/10.1007/s10875-010-9423-4 google scholar
13. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265. https://doi.org/10.1007/s10875-006-9021-7 google scholar
14. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs 2007;21:105. https://doi.org/10.2165/00063030-200721020-00005 google scholar
15. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525. https://doi.org/10.1016/j.jaci.2006.01.015 google scholar
16. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803. https://doi.org/10.1016/j.iac.2008.06.006 google scholar
17. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011;139:133. https://doi.org/10.1016/j.clim.2011.01.006 google scholar
18. Waniewski J, Gardulf A, Hammarström L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994;14:90. https://doi.org/10.1007/BF01541341 google scholar
19. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011;139:133. https://doi.org/10.1016/j.clim.2011.01.006 google scholar
20. Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol 2013;33:49. https://doi.org/10.1007/s10875-012-9776-y google scholar
21. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics 2012;6:277-87. https://doi.org/10.2147/BTT.S25188 google scholar
22. Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol 2015;179:146. https://doi.org/10.1111/cei.12485 google scholar
23. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210. https://doi.org/10.1016/j.jaci.2008.04.044 google scholar
24. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies- -a prospective, multi-national study. J Clin Immunol 2006;26:177. https://doi.org/10.1007/s10875-006-9002-x google scholar
25. Markvardsen LH, Christiansen I, Andersen H, Jakobsen J. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin. Basic Clin Pharmacol Toxicol 2015;117:409- 12. https://doi.org/10.1111/bcpt.12428 google scholar
26. Epstein JS, Zoon KC. Dear doctor letter - important drug warning: immune globulin intravenous (human). FDA Med Watch. US Food and Drug Administration; 1998. google scholar
27. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev 2003;17:241-51. https://doi.org/10.1016/S0887-7963(03)00038-5 google scholar
28. Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatrica 2007;96:1474-8. https://doi.org/10.1111/j.1651-2227.2007.00485.x google scholar
29. Sundin U, Nava S, Hammarstrom L. Induction of unresponsiveness against IgA in IgA- deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112:341-6. https://doi.org/10.1046/j.1365-2249.1998.00571.x google scholar
30. Karakoç Aydıner E, Kıykım A, Barıs S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars 2016;51:8-14. https://doi.org/10.5152/TurkPediatriArs.2016.3058 google scholar
31. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. J Clin Immunol 2012;32:1180-92. https://doi.org/10.1007/s10875-012-9720-1 google scholar
32. Bonilla FA, Duff C. Subcutaneous Immunoglobulin Replacement. Immune Deficiency Foundation: Clinical Focus 2015;16:1-16. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format

EXPORT

APA

Kara, M., & Somer, A. (2017). Subcutaneous Immunoglobulin Use in Children. Journal of Child, 17(4), 146-150. https://doi.org/10.5222/j.child.2017.146

AMA

Kara M, Somer A. Subcutaneous Immunoglobulin Use in Children. Journal of Child. 2017;17(4):146-150. https://doi.org/10.5222/j.child.2017.146

ABNT

Kara, M.; Somer, A. Subcutaneous Immunoglobulin Use in Children. Journal of Child, [Publisher Location], v. 17, n. 4, p. 146-150, 2017.

Chicago: Author-Date Style

Kara, Manolya, and Ayper Somer. 2017. “Subcutaneous Immunoglobulin Use in Children.” Journal of Child 17, no. 4: 146-150. https://doi.org/10.5222/j.child.2017.146

Chicago: Humanities Style

Kara, Manolya, and Ayper Somer. “Subcutaneous Immunoglobulin Use in Children.” Journal of Child 17, no. 4 (Apr. 2024): 146-150. https://doi.org/10.5222/j.child.2017.146

Harvard: Australian Style

Kara, M & Somer, A 2017, 'Subcutaneous Immunoglobulin Use in Children', Journal of Child, vol. 17, no. 4, pp. 146-150, viewed 25 Apr. 2024, https://doi.org/10.5222/j.child.2017.146

Harvard: Author-Date Style

Kara, M. and Somer, A. (2017) ‘Subcutaneous Immunoglobulin Use in Children’, Journal of Child, 17(4), pp. 146-150. https://doi.org/10.5222/j.child.2017.146 (25 Apr. 2024).

MLA

Kara, Manolya, and Ayper Somer. “Subcutaneous Immunoglobulin Use in Children.” Journal of Child, vol. 17, no. 4, 2017, pp. 146-150. [Database Container], https://doi.org/10.5222/j.child.2017.146

Vancouver

Kara M, Somer A. Subcutaneous Immunoglobulin Use in Children. Journal of Child [Internet]. 25 Apr. 2024 [cited 25 Apr. 2024];17(4):146-150. Available from: https://doi.org/10.5222/j.child.2017.146 doi: 10.5222/j.child.2017.146

ISNAD

Kara, Manolya - Somer, Ayper. “Subcutaneous Immunoglobulin Use in Children”. Journal of Child 17/4 (Apr. 2024): 146-150. https://doi.org/10.5222/j.child.2017.146

Volume 17, Issue 42017, P. 146-150

TIMELINE

Submitted	20.11.2017
Accepted	26.01.2018

LICENCE

Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.

Journal of Child

Review

Subcutaneous Immunoglobulin Use in Children

Çocuklarda Subkutan İmmünglobülin Kullanımı

PDF View

References

Citations

EXPORT

APA

AMA

ABNT

Chicago: Author-Date Style

Chicago: Humanities Style

Harvard: Australian Style

Harvard: Author-Date Style

MLA

Vancouver

ISNAD

TIMELINE

LICENCE

SHARE